Pfizer Donates All Profits in Russia to Ukraine

South San Francisco, CA, USA - Feb 8, 2020: American multinational pharmaceutical corporation Pfizer's South San Francisco office.
hapabapa / Getty Images

Pfizer has announced that effective immediately, it will donate all profits of its Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.

“This will be in addition to all other recently announced donations from Pfizer to Ukraine,” the pharmaceutical company said in a March 14 announcement. “Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created.”

See: Russia’s Default ‘Imminent’- What Does This Mean for US Economy?
Gas Prices 101: How Growing Need for Fuel Surcharges Affects Businesses (and You)

For humanitarian reasons, medicines were excluded from the sanctions imposed on Russia and Pfizer said that a voluntary pause in the flow of its medicines to Russia “would be in direct violation of our foundational principle of putting patients first.”

Make Your Money Work Better for You

“Ending delivery of medicines, including cancer or cardiovascular therapies, would cause significant patient suffering and potential loss of life, particularly among children and elderly people.”

However, the company said it will no longer initiate new clinical trials in Russia, and will stop recruiting new patients in ongoing clinical trials in the country.

Pfizer added it will work with the FDA and other regulators to transition all ongoing clinical trials to alternative sites outside Russia.

“Finally, while Pfizer doesn’t own or operate any manufacturing sites in Russia, we will cease all planned investments with local suppliers intended to build manufacturing capacity in the country,” the company said. “These decisions align with our patient-first values and ensure that every dollar of profit derived from Russia will strengthen Ukraine and its people as they continue to valiantly defend their nation and freedom from this unprovoked and unjustified attack.”

Following Pfizer’s announcement, California Rep. Anna G. Eshoo, who is calling for pharmaceutical companies to direct profits made in Russia to Ukraine, released a statement asking for other pharmaceutical companies to follow suit.

See: How Much Will Pfizer and Moderna Be Worth by the End of 2022?
Find: How Much Does the President Control Gas Prices?

“As the U.S. and its international partners respond to the unprovoked aggression of Russia by imposing unprecedented sanctions across many sectors, medicines, for humanitarian reasons, are not included. Today, Pfizer announced that it will maintain its supply of medicines, including cancer and cardiovascular therapies, in Russia, but any and all profits will be directed to the enormous humanitarian needs of the Ukrainian people,” Eshoo said.

Make Your Money Work Better for You

“I call on every drug company in the U.S. to follow this example. The Russian people need these medicines. The Ukrainian people need so much more and I hope every penny earned in Russia by every drug company is used to help them,” she added.

More From GOBankingRates

Share this article:

Make Your Money Work Better for You

About the Author

Yaël Bizouati-Kennedy is a full-time financial journalist and has written for several publications, including Dow Jones, The Financial Times Group, Bloomberg and Business Insider. She also worked as a vice president/senior content writer for major NYC-based financial companies, including New York Life and MSCI. Yaël is now freelancing and most recently, she co-authored  the book “Blockchain for Medical Research: Accelerating Trust in Healthcare,” with Dr. Sean Manion. (CRC Press, April 2020) She holds two master’s degrees, including one in Journalism from New York University and one in Russian Studies from Université Toulouse-Jean Jaurès, France.
Learn More

Best Bank Accounts for September 2022

Untitled design (1)
Close popup The GBR Closer icon

Sending you timely financial stories that you can bank on.

Sign up for our daily newsletter for the latest financial news and trending topics.

Loading...
Please enter an email.
Please enter a valid email address.
There was an unknown error. Please try again later.

For our full Privacy Policy, click here.